
AlphaFold 3's Protein-Ligand Predictions Are Now Accurate Enough to Replace Early-Stage Drug Screening
Google DeepMind's AlphaFold 3 has crossed a critical threshold in binding affinity prediction, with new benchmarks showing it matches or beats traditional experimental screening on 73% of tested drug targets — reshaping how pharmaceutical companies spend their first two years of R&D.








